212 related articles for article (PubMed ID: 38225213)
21. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.
Edlind MP; Hsieh AC
Asian J Androl; 2014; 16(3):378-86. PubMed ID: 24759575
[TBL] [Abstract][Full Text] [Related]
22. MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.
Offermann A; Vlasic I; Syring I; Vogel W; Ruiz C; Zellweger T; Rentsch CA; Hagedorn S; Behrends J; Nowak M; Merseburger A; Bubendorf L; Kirfel J; Duensing S; Adler D; Perner S
Oncotarget; 2017 Jan; 8(5):7964-7976. PubMed ID: 27974704
[TBL] [Abstract][Full Text] [Related]
23. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
24. Ursolic Acid Induces Apoptosis of Prostate Cancer Cells via the PI3K/Akt/mTOR Pathway.
Meng Y; Lin ZM; Ge N; Zhang DL; Huang J; Kong F
Am J Chin Med; 2015; 43(7):1471-86. PubMed ID: 26503559
[TBL] [Abstract][Full Text] [Related]
25. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
26. [Effects of Xihuang Pills on proliferation and apoptosis of prostate cancer LNCaP cells based on AR/m TOR signaling pathway].
Dai XJ; Long Y; Zou B; Wu LT; Qiu JF; Wu YR; Deng Z; Wang YL; Zhou Q; Tian XF
Zhongguo Zhong Yao Za Zhi; 2023 Aug; 48(15):4147-4155. PubMed ID: 37802783
[TBL] [Abstract][Full Text] [Related]
27. Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.
Steely AM; Willoughby JA; Sundar SN; Aivaliotis VI; Firestone GL
Anticancer Drugs; 2017 Oct; 28(9):1018-1031. PubMed ID: 28708672
[TBL] [Abstract][Full Text] [Related]
28. Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
Le B; Powers GL; Tam YT; Schumacher N; Malinowski RL; Steinke L; Kwon G; Marker PC
PLoS One; 2017; 12(3):e0174658. PubMed ID: 28350865
[TBL] [Abstract][Full Text] [Related]
29. AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways.
Tortorella E; Giantulli S; Sciarra A; Silvestri I
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768370
[TBL] [Abstract][Full Text] [Related]
30. A selective androgen receptor modulator, S4, displays robust anti-cancer activity on hepatocellular cancer cells by negatively regulating PI3K/AKT/mTOR signalling pathway.
Yavuz M; Takanlou LS; Avcı ÇB; Demircan T
Gene; 2023 Jun; 869():147390. PubMed ID: 36990257
[TBL] [Abstract][Full Text] [Related]
31. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
Yan G; Ru Y; Wu K; Yan F; Wang Q; Wang J; Pan T; Zhang M; Han H; Li X; Zou L
Prostate; 2018 Feb; 78(3):166-177. PubMed ID: 29181846
[TBL] [Abstract][Full Text] [Related]
32. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
33. Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways.
Lu X; Yang F; Chen D; Zhao Q; Chen D; Ping H; Xing N
Int J Biol Sci; 2020; 16(7):1121-1134. PubMed ID: 32174789
[TBL] [Abstract][Full Text] [Related]
34. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer.
Ellis L; Ku SY; Ramakrishnan S; Lasorsa E; Azabdaftari G; Godoy A; Pili R
Oncotarget; 2013 Dec; 4(12):2225-36. PubMed ID: 24163230
[TBL] [Abstract][Full Text] [Related]
35. Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer.
Li B; Lu W; Yang Q; Yu X; Matusik RJ; Chen Z
Prostate; 2014 Apr; 74(4):421-32. PubMed ID: 24347472
[TBL] [Abstract][Full Text] [Related]
36. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
[TBL] [Abstract][Full Text] [Related]
37. Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival.
Rokhlin OW; Taghiyev AF; Bayer KU; Bumcrot D; Koteliansk VE; Glover RA; Cohen MB
Cancer Biol Ther; 2007 May; 6(5):732-42. PubMed ID: 17387273
[TBL] [Abstract][Full Text] [Related]
38. [Inhibition effect of active fraction from clove on PI3K/Akt/mTOR signaling pathway to induce apoptosis of human colon cancer HCT116 cells].
Zhao G; Zhang D; Yang XH; Li XF; Liu MH
Zhongguo Zhong Yao Za Zhi; 2021 Mar; 46(5):1197-1204. PubMed ID: 33787115
[TBL] [Abstract][Full Text] [Related]
39. Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer.
Yadav SS; Li J; Stockert JA; O'Connor J; Herzog B; Elaiho C; Galsky MD; Tewari AK; Yadav KK
Oncotarget; 2016 Nov; 7(46):76181-76196. PubMed ID: 27783994
[TBL] [Abstract][Full Text] [Related]
40. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers.
Lin HK; Hu YC; Yang L; Altuwaijri S; Chen YT; Kang HY; Chang C
J Biol Chem; 2003 Dec; 278(51):50902-7. PubMed ID: 14555644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]